Viatris (VTRS) Stock Price, Fundamentals & Analysis

What VTRS does

Viatris (VTRS) is a healthcare stock listed on the US market that operates across North America, Europe, China, and other regions through four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company supplies prescription brand drugs, generic drugs, complex generic drugs, and biosimilars, covering therapeutic areas such as cardiovascular, oncology, diabetes and metabolism, immunology, and respiratory and allergy. It also provides support services like diagnostic clinics, educational seminars, and digital health tools to patients, and distributes medicines in oral solid doses, injectables, and complex dosage forms to pharmacies, wholesalers, payers, insurers, and governments.

Key numbers explained

• 17.12 USD is the current share price, the amount you would pay for one share at this moment.
• -0.35% is today's price change, showing the stock is slightly down on the session.
• The forward P/E ratio of 6.4 divides the share price by expected future earnings; a lower number can suggest the stock is priced modestly relative to those expectations.
• The dividend yield of 2.79% tells you the annual dividend as a percentage of the current price, indicating the cash return shareholders receive from dividends alone.
• 960% is the share of earnings paid out as dividends, meaning the company distributes many times its reported earnings as dividends, often funded by other sources of cash.
• 19.66B USD is the market capitalisation, the total value of all outstanding shares at the current price.
• 0.88 is the beta, a measure of volatility relative to the market; a beta below 1 suggests the stock tends to move less than the overall market.
• The 52-week range of 9.43 – 18.39 shows the lowest and highest prices over the past year, with the current price near the upper end of that span.

Recent news

Recent headlines note that Oppenheimer initiated coverage of Viatris with an Outperform rating and a 25 price target, and that Viatris won Japan approval for WAKIX, a step that could help it build a meaningful specialty business. Other stories mention Viatris facing multiple paths to earnings growth, and broader industry topics such as Gilead expanding lenacapavir licensing for HIV prevention and treatment, and a look at US stocks that could gain if buyers shift away from India.

What to watch

Investors tracking Viatris often consider how its earnings growth paths, specialty business approvals, and dividend policy interact with broader sector trends. Because Viatris is part of the S&P 500, its performance can be influenced by the same macro and healthcare-sector factors that affect peers like Moderna (MRNA), CVS Health (CVS), Revvity (RVTY), Veeva Systems (VEEV), Gilead Sciences (GILD), Lilly (Eli) (LLY), and Amgen (AMGN). Key factors to monitor include drug approval pipelines, pricing and reimbursement dynamics, debt levels, and currency movements across its global markets.